Shots:

• The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA SCCHN
• The companies have accepted DMC’s recommendation to terminate the P-III JAVELIN Head and Neck 100 study as it did not meet its 1EPs i.e. improvement in PFS. A detailed analysis of the Phase III JAVELIN Head and Neck 100 study is being conducted and results will be shared with the scientific community
• Bavencio is a PD-L1 antibody- acts by blocking the interaction of PD-L1 with PD-1 receptors. In Nov’2014- Merck KGaA and Pfizer signed an agreement to co-develop and co-commercialize Bavencio

Click here ­to­ read full press release/ article | Ref: EMD Sereno | Image: Blau Journal